Fintech PR

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Published

on

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study

Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort

Cash position of $19.6 million as of September 30, 2024

Management hosting conference call and webcast today at 8:30 a.m. ET

SAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial results and operational highlights.

 

 

Wayne Pisano, Chair of Oncolytics’ Board of Directors and Interim CEO, stated, “With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep’s potential in HR+/HER2- metastatic breast cancer. After discussions with regulators and key opinion leaders and based on an estimated overall survival benefit of more than a year provided by pelareorep-based therapy, a registration-enabling study that is designed to support an accelerated approval is the next logical step for the development of pelareorep.” Pisano continued, “We continue to develop our gastrointestinal cancer program and look forward to presenting updated efficacy data from our anal cancer cohort and safety data from our new modified FOLFIRNOX pancreatic cancer cohort. Both of these indications represent a significant unmet medical need, and we have shown pelareorep provides the potential to meaningfully improve patient outcomes. This coming year will be critical for pelareorep, as well as for Oncolytics, and I’ve never been more confident in the potential pelareorep can deliver to cancer patients in need.”

Third Quarter Highlights

BRACELET-1 data exceeds expectations, providing clear evidence of pelareorep’s ability to improve outcomes in patients with advanced HR+/HER2- breast cancer (link to press release), demonstrating progression-free survival of 12.1 months for pelareorep + paclitaxel compared to 6.4 months for paclitaxel alone, yielding a benefit of 5.7 months. Additionally, 64% of patients treated with pelareorep + paclitaxel lived at least two years compared to only 33% of patients treated with paclitaxel alone. Overall survival could not be calculated as more than half of the pelareorep + paclitaxel patients were alive at the end of the study. Assuming the remaining patients survived only until their next planned follow-up visit, the median overall survival would have been 32.1 months, which compares favorably to the 18.2 months recorded for patients who received paclitaxel monotherapy.

Advertisement

Financial Highlights

  • As of September 30, 2024, the Company reported $19.6 million in cash and cash equivalents. The Company has a projected cash runway through key milestones and into 2025.
  • The net loss for the third quarter of 2024 was $9.5 million, compared to a net loss of $9.9 million for the third quarter of 2023. The basic and diluted loss per share was $0.12 in the third quarter of 2024, compared to a basic and diluted loss per share of $0.14 in the third quarter of 2023.
  • Research and development expenses for the third quarter of 2024 were $6.8 million, compared to $5.8 million for the third quarter of 2023. The increase was primarily due to higher manufacturing expenses and clinical trial expenses.  
  • General and administrative expenses for the third quarter of 2024 were $3.1 million, compared with $5.2 million for the third quarter of 2023. The decrease was primarily due to lower investor relations activities and transaction costs as part of our public offering in 2023.
  • Net cash used in operating activities for the nine months ended September 30, 2024 was $19.1 million, compared to $22.3 million for the nine months ended September 30, 2023. The decrease reflected non-cash working capital changes, partly offset by higher net operating activities in 2024.

Recent and Anticipated Milestones

  • H1 2025: Finalize master protocol for the adaptive registration-enabling trial for pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab in first-line pancreatic ductal adenocarcinoma (PDAC) with the Global Coalition for Adaptive Research (GCAR) and submit it to the FDA
  • H1 2025: Safety run-in data from cohort 5 of the GOBLET study, investigating pelareorep and modified FOLFIRNOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed pancreatic cancer
  • H1 2025: updated efficacy data from cohort 4 of the GOBLET study, investigating pelareorep and atezolizumab in second-line or later anal cancer
  • Mid 2025: First patient enrolled in registration-enabling study evaluating pelareorep and paclitaxel in metastatic HR+/HER2- breast cancer
  • H2 2025: Initial efficacy results from cohort 5 of the GOBLET study, investigating pelareorep and mFOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic cancer

Webcast and Conference Call

Management will host a conference call for analysts and investors at 8:30 a.m. ET today, November 12, 2024. To access the call, please dial (888) 510-2154 (North America) or (437) 900-0527 (International), and if needed, provide Conference ID: 68336. To join the conference call without operator assistance, please click here. A live webcast of the call will also be available by clicking here or on the Investor Relations page of Oncolytics’ website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 68336#.

ONCOLYTICS BIOTECH INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(unaudited)

(in thousands of Canadian dollars, except share amounts)

As at

September 30,
2024

December 31,
2023

Assets

Advertisement

Current assets

Cash and cash equivalents

$              19,598

$                       34,912

Other receivables

104

15

Prepaid expenses

2,119

3,246

Advertisement

Warrant derivative

1,092

Total current assets

22,913

38,173

Property and equipment

422

282

Right-of-use assets

Advertisement

927

365

Total assets

$              24,262

$                       38,820

Liabilities and Shareholders’ Equity

Current liabilities

Accounts payable and accrued liabilities

$                 6,922

$                         3,572

Advertisement

Other liabilities

489

332

Lease liabilities

251

133

Warrant derivative

200

Total current liabilities

Advertisement

7,662

4,237

Contract liability

6,730

6,730

Lease liabilities

813

290

Total liabilities

15,205

Advertisement

11,257

Commitments

Shareholders’ equity

Share capital

  Authorized: unlimited

  Issued: September 30, 2024 – 77,074,089

  December 31, 2023 – 74,423,960

434,460

430,906

Contributed surplus

Advertisement

43,640

42,116

Accumulated other comprehensive income

653

544

Accumulated deficit

(469,696)

(446,003)

Total shareholders’ equity

9,057

Advertisement

27,563

Total liabilities and shareholders’ equity

$              24,262

$                       38,820

 

 

ONCOLYTICS BIOTECH INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands of Canadian dollars, except share amounts)

Advertisement

Three Months Ended
September 30,

Nine Months Ended
September 30,

2024

2023

2024

2023

Expenses

   Research and development

$              6,794

$              5,811

Advertisement

$            17,095

$            13,051

   General and administrative

3,105

5,237

9,450

11,891

Loss before the following

(9,899)

(11,048)

Advertisement

(26,545)

(24,942)

   Change in fair value of warrant derivative

229

515

1,333

439

   Foreign exchange (loss) gain

(122)

310

Advertisement

579

(83)

   Interest income, net

261

305

1,047

837

Loss before income taxes

(9,531)

(9,918)

Advertisement

(23,586)

(23,749)

   Income tax expense

(12)

(7)

(107)

(54)

Net loss

(9,543)

(9,925)

Advertisement

(23,693)

(23,803)

Other comprehensive (loss) income items that may be
reclassified to net loss

  Translation adjustment

(69)

101

109

(7)

Net comprehensive loss

$            (9,612)

Advertisement

$            (9,824)

$          (23,584)

$          (23,810)

Basic and diluted loss per common share

$              (0.12)

$              (0.14)

$              (0.31)

$              (0.36)

Weighted average number of shares (basic and
diluted)

77,016,848

Advertisement

69,803,255

76,120,580

65,565,890

 

 

ONCOLYTICS BIOTECH INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(unaudited)

(in thousands of Canadian dollars)

Share Capital

Advertisement

Contributed
Surplus

Accumulated
Other
Comprehensive
Income

Accumulated
Deficit

Total

As at December 31, 2022

$           404,040

$             40,051

$                     662

$         (418,251)

$             26,502

Advertisement

Net loss and other comprehensive loss

(7)

(23,803)

(23,810)

Issued pursuant to stock option plan

662

(256)

Advertisement

406

Issued pursuant to “At the Market” Agreement

9,128

9,128

Issued pursuant to public offering

17,724

Advertisement

638

18,362

Share issue costs

(2,728)

(2,728)

Advertisement

Share-based compensation expense

1,158

1,158

As at September 30, 2023

$           428,826

$             41,591

$                     655

Advertisement

$         (442,054)

$             29,018

As at December 31, 2023

$           430,906

$             42,116

$                     544

$         (446,003)

$             27,563

Net loss and other comprehensive income

Advertisement

109

(23,693)

(23,584)

Issued pursuant to incentive share award plan

3

(3)

Advertisement

Issued pursuant to “At the Market” Agreement

4,062

4,062

Issued pursuant to warrant derivative exercised

71

Advertisement

71

Share issue costs

(582)

(582)

Share-based compensation expense

Advertisement

1,527

1,527

As at September 30, 2024

$           434,460

$             43,640

$                     653

$         (469,696)

$                9,057

Advertisement

 

 

ONCOLYTICS BIOTECH INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands of Canadian dollars) 

Nine Months Ended September 30,

2024

2023

Operating Activities

Advertisement

Net loss for the period

$               (23,693)

$              (23,803)

Depreciation – property and equipment

92

62

Depreciation – right-of-use-assets

234

234

Share-based compensation expense

Advertisement

1,527

1,158

Compensation warrant expenses

151

Interest expense on lease liabilities

99

53

Unrealized foreign exchange (gain) loss

(544)

Advertisement

21

Change in fair value of warrant derivative

(1,333)

(439)

Net change in non-cash working capital

4,498

239

Cash used in operating activities

(19,120)

(22,324)

Advertisement

Investing Activities

Acquisition of property and equipment

(233)

(5)

Maturities of marketable securities

20,230

Cash (used in) provided by investing activities

(233)

20,225

Advertisement

Financing Activities

Proceeds from exercise of stock options

406

Proceeds from exercise of warrant derivative

65

Proceeds from “At the Market” equity distribution agreement, net

3,480

8,790

Advertisement

Proceeds from public offering

21,359

Payment of lease liabilities

(248)

(303)

Cash provided by financing activities

3,297

30,252

(Decrease) increase in cash and cash equivalents

Advertisement

(16,056)

28,153

Cash and cash equivalents, beginning of period

34,912

11,666

Impact of foreign exchange on cash and cash equivalents

742

162

Cash and cash equivalents, end of period

$                 19,598

Advertisement

$                39,981

 

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic, including pelareorep’s potential in HR+/HER2- metastatic breast cancer and the estimated overall survival benefit of pelareorep-based therapy; our belief that pelareorep is poised to advance to a registration-enabling study; continued development of our gastrointestinal cancer program; our expectations regarding the presentation of efficacy and safety data from anal and pancreatic cancer cohorts; the potential market and commercial opportunities for pelareorep; our confidence in pelareorep’s potential to meaningfully improve patient outcomes; Oncolytics’ projected cash runway; our plan to conduct a registration-enabling study to assess pelareorep-based combination therapy in patients with advanced HR+/HER2- breast cancer and the anticipated timing thereof; and other statements related to anticipated developments in Oncolytics’ business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics’ ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics’ quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

 

Company Contact

Jon Patton

Director of IR & Communication

Advertisement

jpatton@oncolytics.ca

Investor Relations for Oncolytics

Timothy McCarthy

LifeSci Advisors

+1-917-679-9282

tim@lifesciadvisors.com

 

 Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/oncolytics-biotech-reports-third-quarter-2024-financial-results-and-operational-highlights-302302466.html

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version